Monimus Capital Management LP purchased a new position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 137,058 shares of the company's stock, valued at approximately $1,621,000. Roivant Sciences comprises 1.5% of Monimus Capital Management LP's holdings, making the stock its 25th biggest holding.
Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Gladius Capital Management LP acquired a new stake in shares of Roivant Sciences during the 3rd quarter worth approximately $35,000. US Bancorp DE grew its stake in shares of Roivant Sciences by 146.5% in the 3rd quarter. US Bancorp DE now owns 3,278 shares of the company's stock valued at $38,000 after buying an additional 1,948 shares during the period. GAMMA Investing LLC raised its holdings in Roivant Sciences by 57.0% during the fourth quarter. GAMMA Investing LLC now owns 3,548 shares of the company's stock worth $42,000 after buying an additional 1,288 shares during the last quarter. PNC Financial Services Group Inc. raised its holdings in shares of Roivant Sciences by 27.0% in the fourth quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company's stock valued at $84,000 after purchasing an additional 1,507 shares during the last quarter. Finally, Quarry LP raised its stake in shares of Roivant Sciences by 50.0% during the 3rd quarter. Quarry LP now owns 7,500 shares of the company's stock worth $87,000 after purchasing an additional 2,500 shares during the period. Institutional investors own 64.76% of the company's stock.
Roivant Sciences Trading Up 2.1 %
ROIV traded up $0.23 during trading on Wednesday, reaching $10.94. The stock had a trading volume of 15,753,336 shares, compared to its average volume of 5,537,497. The stock's 50 day moving average is $10.78 and its two-hundred day moving average is $11.48. The company has a market capitalization of $7.81 billion, a price-to-earnings ratio of -72.93 and a beta of 1.26. Roivant Sciences Ltd. has a one year low of $9.76 and a one year high of $13.06.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last posted its quarterly earnings data on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, beating analysts' consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. On average, equities research analysts predict that Roivant Sciences Ltd. will post -0.92 earnings per share for the current year.
Insiders Place Their Bets
In related news, COO Eric Venker sold 100,000 shares of the business's stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $10.65, for a total transaction of $1,065,000.00. Following the completion of the sale, the chief operating officer now directly owns 896,869 shares in the company, valued at approximately $9,551,654.85. The trade was a 10.03 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CAO Rakhi Kumar sold 227,500 shares of the business's stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $10.43, for a total transaction of $2,372,825.00. Following the sale, the chief accounting officer now directly owns 163,264 shares of the company's stock, valued at approximately $1,702,843.52. The trade was a 58.22 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,975,586 shares of company stock valued at $22,640,661. Corporate insiders own 7.90% of the company's stock.
Wall Street Analysts Forecast Growth
Several research firms recently commented on ROIV. Cantor Fitzgerald raised shares of Roivant Sciences to a "strong-buy" rating in a report on Tuesday, March 4th. HC Wainwright reissued a "buy" rating and set a $18.00 price objective on shares of Roivant Sciences in a report on Tuesday, February 11th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Roivant Sciences presently has an average rating of "Buy" and an average price target of $18.08.
Check Out Our Latest Stock Report on Roivant Sciences
About Roivant Sciences
(
Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Featured Articles
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
